Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (577)	3/9/2005 6:15:57 PM
From: tuck	Read Replies (1) of 946

The patient populations being studied in the various Stellar trials are rather different. For example, there seems to be more variety in the Stellar 2 population than the Stellar 4: Stellar 2: cancer.gov Stellar 3: cancer.gov Stellar 4: cancer.gov 3 & 4 are the same. If the issue was poor data in historical survival data for PS 2 Stage IIIB/IV patients, that issue goes away to some extent in Stellar 2. Also in Stellar 4, since we're talking a different drug class. Maybe more hope for success than some think? Comments? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next